Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Arterioscler Thromb Vasc Biol ; 35(4): 930-7, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25722431

RESUMO

OBJECTIVE: The hypothesis that hypertension induces a hypercoagulable state arises from the complications associated with hypertension: stroke and myocardial infarction. Here, we determine whether hypertension causes changes in the thrombin-generating capacity of the vascular wall. APPROACH AND RESULTS: We used spontaneously hypertensive rats (SHR) compared with Wistar rats. The addition of thoracic aortic rings of SHR to a Wistar or SHR plasma pool resulted in a greater increase in thrombin generation compared with equivalent rings from Wistar. This increase occurred in 12- but not 5-week-old rats and was prevented by an angiotensin II-converting enzyme inhibitor, indicating that established hypertension is required to induce increased thrombin generation within the vessel wall. Whereas no difference was observed for endothelial cells, thrombin formation was higher on aortic smooth muscle cells (SMCs) from SHR than on those from Wistar. Exposure of negatively charged phospholipids was higher on SHR than on Wistar rings, as well as on cultured SMCs. Tissue factor activity was higher in SHR SMCs. Twelve-week-old SHR exhibited accelerated FeCl3-induced thrombus formation in carotid arteries, and the resulting occlusive thrombi were disaggregated by blockade of glycoprotein Ibα-von Willebrand factor interactions. SHR SMCs were more sensitive to thrombin-induced proliferation than Wistar SMCs. This effect was totally abolished by a protease-activated receptor 1 inhibitor. CONCLUSIONS: The prothrombotic phenotype of the SHR vessel wall was due to the ability of SMCs to support greater thrombin generation and resulted in accelerated occlusive thrombus formation after arterial injury, which was sensitive to glycoprotein Ibα-von Willebrand factor inhibitors.


Assuntos
Coagulação Sanguínea , Hipertensão/complicações , Músculo Liso Vascular/metabolismo , Miócitos de Músculo Liso/metabolismo , Trombose/etiologia , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Animais , Anti-Hipertensivos/farmacologia , Aorta Torácica/metabolismo , Aorta Torácica/fisiopatologia , Coagulação Sanguínea/efeitos dos fármacos , Pressão Sanguínea , Células Cultivadas , Modelos Animais de Doenças , Células Endoteliais/metabolismo , Fibrinolíticos/farmacologia , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Hipertensão/genética , Hipertensão/fisiopatologia , Masculino , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/fisiopatologia , Miócitos de Músculo Liso/efeitos dos fármacos , Fenótipo , Agregação Plaquetária , Inibidores da Agregação Plaquetária/farmacologia , Complexo Glicoproteico GPIb-IX de Plaquetas/antagonistas & inibidores , Complexo Glicoproteico GPIb-IX de Plaquetas/metabolismo , Ratos Endogâmicos SHR , Ratos Wistar , Receptor PAR-1/antagonistas & inibidores , Receptor PAR-1/metabolismo , Trombina/metabolismo , Tromboplastina/metabolismo , Trombose/sangue , Trombose/genética , Trombose/fisiopatologia , Trombose/prevenção & controle , Fatores de Tempo , Remodelação Vascular , Fator de von Willebrand/antagonistas & inibidores , Fator de von Willebrand/metabolismo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa